EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Obinutuzumab as a Rescue and Maintenance Strategy in Children with Difficult-to-Treat Nephrotic Syndrome After Rituximab-Based Treatment Failure or Intolerance: A Preliminary Single-Center Real-World Retrospective Study

Haoqiong Sun, Ling Guo, Panpan Shao, Wenpei Liang, Xueqing Ma, Yonghua He, Liru Qiu

Drug Design, Development and Therapy · 2026-07 · Volume 20 · 1-11

DOI: 10.2147/dddt.s619807 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-07. Verfasst von Haoqiong Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Rituximab, Nephrotic Syndrome. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This preliminary study aimed to describe the effectiveness and safety of obinutuzumab as a rescue and maintenance anti-CD20 strategy in children with difficult-to-treat nephrotic syndrome after failure or intolerance of rituximab-based multi-target immunosuppression. Patients and Methods: This exploratory single-center retrospective real-world study included consecutive children who received obinutuzumab between April 2024 and January 2025. Nine patients were included in the safety set, and eight who completed treatment and had follow-up data comprised the efficacy set. The primary outcome was 12-month relapse-free survival. Secondary outcomes included annualized relapse rate, peripheral B-cell depletion, glucocorticoid-free status, reduction or discontinuation of background immunosuppression, and safety.

Results

Median follow-up in the efficacy set was 1.24 years (IQR 1.01-1.67). No relapses occurred after obinutuzumab in this small efficacy set, corresponding to an observed 12-month relapse-free proportion of 8/8 (100%; exact 95% CI 63.1-100) and reducing the annualized relapse rate from 2.50 to 0 episodes/person-year. All eight efficacy-set patients achieved complete peripheral B-cell depletion and remained depleted at 6 months. At last follow-up, seven had discontinued both glucocorticoids and all non-obinutuzumab immunosuppressants, while one had discontinued glucocorticoids with a reduced dose of mycophenolate mofetil. In the safety set, one child developed severe anaphylactic shock during the first infusion; infectious events were limited to CTCAE grade 1-2 events.

Conclusion

In this exploratory, hypothesis-generating study, obinutuzumab was associated with a favorable relapse profile, sustained peripheral B-cell depletion, and reduction of background immunosuppression in a highly selected pediatric population. Larger prospective studies are required to confirm these preliminary observations and define long-term safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedRituximabNephrotic SyndromeHumansRetrospective StudiesChildMaleFemaleChild, PreschoolTreatment FailureAdolescent

Stichwörter der Autor:innen

B-cell depletionchilddifficult-to-treat nephrotic syndromeobinutuzumabrituximab

Substanzen

Antibodies, Monoclonal, HumanizedRituximabobinutuzumab

Autor:innen und Institutionen

  • Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
  • Hubei Provincial Key Laboratory of Pediatric Genetic Metabolic and Endocrine Rare Diseases, Wuhan, 430030, People's Republic of China.
  • Hubei Provincial Clinical Research Center for Children's Growth and Development and Metabolic Diseases, Wuhan, 430030, People's Republic of China.

Zitieren

APA

Sun, H., Guo, L., Shao, P., Liang, W., Ma, X., He, Y., & Qiu, L. (2026). Obinutuzumab as a Rescue and Maintenance Strategy in Children with Difficult-to-Treat Nephrotic Syndrome After Rituximab-Based Treatment Failure or Intolerance: A Preliminary Single-Center Real-World Retrospective Study. Drug Design, Development and Therapy, Volume 20, 1-11. https://doi.org/10.2147/dddt.s619807

Vancouver

Sun H, Guo L, Shao P, Liang W, Ma X, He Y, et al. Obinutuzumab as a Rescue and Maintenance Strategy in Children with Difficult-to-Treat Nephrotic Syndrome After Rituximab-Based Treatment Failure or Intolerance: A Preliminary Single-Center Real-World Retrospective Study. Drug Design, Development and Therapy. 2026;Volume 20:1-11. doi:10.2147/dddt.s619807

BibTeX
@article{Sun2026,
  author = {Sun, Haoqiong and Guo, Ling and Shao, Panpan and Liang, Wenpei and Ma, Xueqing and He, Yonghua and Qiu, Liru},
  title = {Obinutuzumab as a Rescue and Maintenance Strategy in Children with Difficult-to-Treat Nephrotic Syndrome After Rituximab-Based Treatment Failure or Intolerance: A Preliminary Single-Center Real-World Retrospective Study},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--11},
  doi = {10.2147/dddt.s619807}
}
Kostenlos starten →